JP2022520061A - 治療薬および治療方法 - Google Patents
治療薬および治療方法 Download PDFInfo
- Publication number
- JP2022520061A JP2022520061A JP2021546264A JP2021546264A JP2022520061A JP 2022520061 A JP2022520061 A JP 2022520061A JP 2021546264 A JP2021546264 A JP 2021546264A JP 2021546264 A JP2021546264 A JP 2021546264A JP 2022520061 A JP2022520061 A JP 2022520061A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- methyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962803299P | 2019-02-08 | 2019-02-08 | |
| US62/803,299 | 2019-02-08 | ||
| PCT/US2020/017364 WO2020163823A2 (en) | 2019-02-08 | 2020-02-07 | Therapeutic agents and methods of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520061A true JP2022520061A (ja) | 2022-03-28 |
| JP2022520061A5 JP2022520061A5 (cg-RX-API-DMAC7.html) | 2023-05-23 |
Family
ID=71948254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546264A Pending JP2022520061A (ja) | 2019-02-08 | 2020-02-07 | 治療薬および治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220169628A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3920923A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022520061A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210137025A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113660937A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020218367A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3127501A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020163823A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023510885A (ja) * | 2020-01-15 | 2023-03-15 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド | 治療用物質および処置方法 |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12673106B2 (en) | 2020-08-28 | 2026-07-07 | University Of Florida Research Foundation, Incorporated | Modulators of nuclear receptor subfamily 4 group A member 1 (NR4A1) and uses thereof |
| JP2024505562A (ja) | 2021-02-02 | 2024-02-06 | レス ラボラトイレス セルビエル | 選択的bcl-xl protac化合物及び使用の方法 |
| US20240408085A1 (en) * | 2021-09-01 | 2024-12-12 | Xizang Haisco Pharmaceutical Co., Ltd. | Compound for degradation of bcl-2 family proteins and medical application thereof |
| US20240398764A1 (en) * | 2021-10-12 | 2024-12-05 | University Of Florida Research Foundation, Incorporated | Methods of treating diseases associated with senescent cell accumulation |
| CN118660886A (zh) | 2021-12-09 | 2024-09-17 | 佛罗里达大学研究基金公司 | 用于治疗癌症的bcl-xl/bcl-2双重降解剂 |
| CA3240051A1 (en) | 2021-12-30 | 2023-07-06 | Beigene Switzerland Gmbh | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| CN116396288B (zh) * | 2022-01-04 | 2026-04-03 | 上海科技大学 | 基于bcl-2家族蛋白配体化合物开发的蛋白降解剂及它们的应用 |
| AU2023264537A1 (en) | 2022-05-06 | 2024-11-14 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| PE20250007A1 (es) | 2022-05-06 | 2025-01-07 | Treeline Biosciences Inc | Degradadores bcl-xl-heterobifuncionales de tetrahidroisoquinolina |
| EP4519260A1 (en) | 2022-05-06 | 2025-03-12 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xdegraders |
| US20260092057A1 (en) * | 2022-05-12 | 2026-04-02 | Kymera Therapeutics, Inc. | Bcl-xl/bcl-2 degraders and uses thereof |
| CN115028679B (zh) * | 2022-08-11 | 2022-11-15 | 深圳湾实验室 | 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用 |
| CN120659777A (zh) * | 2022-10-03 | 2025-09-16 | 佛罗里达大学研究基金公司 | 募集Cereblon的Bcl-xL/Bcl-2双重降解剂 |
| WO2024078581A1 (en) * | 2022-10-12 | 2024-04-18 | Appicine Therapeutics (Hk) Limited | Selective bcl-xl protac compounds and uses thereof |
| CN120569222A (zh) * | 2023-01-18 | 2025-08-29 | 苏州宜联生物医药有限公司 | 包含bcl-2家族蛋白降解剂的抗体药物偶联物及其制备方法和用途 |
| CN121652220A (zh) * | 2023-02-17 | 2026-03-13 | 正大天晴药业集团股份有限公司 | 含有三氟甲磺酰基的化合物 |
| AU2024378690A1 (en) | 2023-11-07 | 2026-05-07 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
| IL327973A (en) | 2023-11-07 | 2026-06-01 | Treeline Biosciences Inc | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| KR20260111020A (ko) | 2023-11-07 | 2026-07-14 | 트리라인 바이오사이언시스, 인크. | 테트라히드로이소퀴놀린 이종이작용성 bcl-xl 분해제 |
| WO2026015489A1 (en) * | 2024-07-08 | 2026-01-15 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders and uses thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017024317A2 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017184995A1 (en) * | 2016-04-21 | 2017-10-26 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof |
| WO2017197055A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| JP2018512449A (ja) * | 2015-03-18 | 2018-05-17 | アルビナス インコーポレイテッド | 標的タンパク質の分解向上のための化合物および方法 |
| WO2018106870A1 (en) * | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| EP3337476A4 (en) * | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US20240398764A1 (en) * | 2021-10-12 | 2024-12-05 | University Of Florida Research Foundation, Incorporated | Methods of treating diseases associated with senescent cell accumulation |
| CN118660886A (zh) * | 2021-12-09 | 2024-09-17 | 佛罗里达大学研究基金公司 | 用于治疗癌症的bcl-xl/bcl-2双重降解剂 |
-
2020
- 2020-02-07 WO PCT/US2020/017364 patent/WO2020163823A2/en not_active Ceased
- 2020-02-07 AU AU2020218367A patent/AU2020218367A1/en not_active Abandoned
- 2020-02-07 KR KR1020217028572A patent/KR20210137025A/ko not_active Ceased
- 2020-02-07 CN CN202080027337.5A patent/CN113660937A/zh active Pending
- 2020-02-07 JP JP2021546264A patent/JP2022520061A/ja active Pending
- 2020-02-07 EP EP20753239.1A patent/EP3920923A4/en not_active Withdrawn
- 2020-02-07 CA CA3127501A patent/CA3127501A1/en active Pending
- 2020-02-07 US US17/429,207 patent/US20220169628A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018512449A (ja) * | 2015-03-18 | 2018-05-17 | アルビナス インコーポレイテッド | 標的タンパク質の分解向上のための化合物および方法 |
| WO2017024317A2 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017184995A1 (en) * | 2016-04-21 | 2017-10-26 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof |
| WO2017197055A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2018106870A1 (en) * | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023510885A (ja) * | 2020-01-15 | 2023-03-15 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド | 治療用物質および処置方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020163823A2 (en) | 2020-08-13 |
| EP3920923A2 (en) | 2021-12-15 |
| KR20210137025A (ko) | 2021-11-17 |
| CN113660937A (zh) | 2021-11-16 |
| AU2020218367A1 (en) | 2021-08-12 |
| WO2020163823A8 (en) | 2020-10-01 |
| WO2020163823A3 (en) | 2020-10-29 |
| CA3127501A1 (en) | 2020-08-13 |
| US20220169628A1 (en) | 2022-06-02 |
| EP3920923A4 (en) | 2022-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220169628A1 (en) | Therapeutic agents and methods of treatment | |
| JP7829523B2 (ja) | 多環式tlr7/8アンタゴニスト及び免疫障害の治療におけるそれらの使用 | |
| AU2020267169B2 (en) | Processes of making and crystalline forms of a MDM2 inhibitor | |
| US12441722B2 (en) | Therapeutic agents and methods of treatment | |
| EP3655401B1 (en) | Tlr7/8 antagonists and uses thereof | |
| US9187434B2 (en) | Substituted 1,5-benzodiazepinones compounds | |
| US10519152B2 (en) | Compounds and their use in treating cancer | |
| JP2025530275A (ja) | 汎kras阻害剤化合物 | |
| CN106255679B (zh) | 用作nav通道抑制剂的杂环化合物及其用途 | |
| KR102653190B1 (ko) | 고 활성 sting 단백질 작용제 화합물 | |
| CA2922532A1 (en) | Aminoheteroaryl benzamides as kinase inhibitors | |
| US9133126B2 (en) | Fluoroalkyl dibenzoazepinone compounds | |
| CN116783183A (zh) | 作为vhl抑制剂用于治疗贫血和癌症的1-(2-(4-环丙基-1h-1,2,3-三唑-1-基)乙酰基)-4-羟基-n-(苄基)吡咯烷-2-甲酰胺衍生物 | |
| KR20240118146A (ko) | 암 치료용 bcl-xl/bcl-2 이중 분해제 | |
| TW202540125A (zh) | 雙環雜芳基化合物 | |
| JP2024508728A (ja) | Nlrp3阻害剤としての化合物 | |
| JP7611591B2 (ja) | Pd-l1拮抗薬化合物 | |
| TW202321244A (zh) | 一種Wnt通路抑制劑化合物 | |
| HK40060209A (en) | Therapeutic agents and methods of treatment | |
| CN116507617B (zh) | 作为vhl抑制剂的1-(2-(4-环丙基-1h-1,2,3-三唑-1-基)乙酰基)-4-羟基吡咯烷-2-甲酰胺衍生物 | |
| KR20180134401A (ko) | 예를 들어 알츠하이머병을 치료하기 위한 선택적 BACE1 억제제로서 N-[3-[2-아미노-5-(1,1-디플루오로에틸)-4,4a,5,7-테트라히드로푸로[3,4-d][1,3]옥사진-7a-일]-4-플루오로-페닐]-5-(트리플루오로메틸)피리딘-2-카르복스아미드 및 그의 (4aR,5S,7aS) 이성질체 | |
| NZ753956B2 (en) | Processes of making and crystalline forms of a mdm2 inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230207 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230512 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240227 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240917 |